TY - JOUR
T1 - Mucins in gastrointestinal cancers.
AU - Turner, Michael S.
AU - McKolanis, John R.
AU - Ramanathan, Ramesh K.
AU - Whitcomb, David C.
AU - Finn, Olivera J.
N1 - Funding Information:
We would like to thank current and former associates and members of our laboratories whose work and ideas are represented in this chapter. We would also like to thank Dr. Joel Weissfeld, Dr. Robert Schoen and Dr. Kim Jessup, our collaborators in the polyp study. Our individual research has been supported for many years by the National Cancer Institute. Our collaborative projects have been supported by the Nathan Arenson Fund for Pancreatic Cancer Research.
PY - 2003
Y1 - 2003
N2 - The mucin family has been under study by molecular biologists, biochemists, pathologists and immunologists interested in cancer because of the role these molecules can play in the diagnosis and treatment of cancer. Immense knowledge has been accumulated, but the high speed of progress in the laboratory has not been matched by the progress towards applying this knowledge in the clinic. For example, specific knowledge of cancer-associated changes in the expression and glycosylation of various mucins, which can aid in the diagnosis as well as prognosis of GI cancers, has not yet led to the use of a panel of anti-mucin antibodies as a standard diagnostic tool. Similarly, many more opportunities exist for using mucin-based therapies than are currently being considered in the clinic. This chapter aimed to highlight some of these opportunities and to interest clinician scientists in exploring them in the near future.
AB - The mucin family has been under study by molecular biologists, biochemists, pathologists and immunologists interested in cancer because of the role these molecules can play in the diagnosis and treatment of cancer. Immense knowledge has been accumulated, but the high speed of progress in the laboratory has not been matched by the progress towards applying this knowledge in the clinic. For example, specific knowledge of cancer-associated changes in the expression and glycosylation of various mucins, which can aid in the diagnosis as well as prognosis of GI cancers, has not yet led to the use of a panel of anti-mucin antibodies as a standard diagnostic tool. Similarly, many more opportunities exist for using mucin-based therapies than are currently being considered in the clinic. This chapter aimed to highlight some of these opportunities and to interest clinician scientists in exploring them in the near future.
UR - http://www.scopus.com/inward/record.url?scp=4444350365&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4444350365&partnerID=8YFLogxK
U2 - 10.1016/s0921-4410(03)21012-7
DO - 10.1016/s0921-4410(03)21012-7
M3 - Review article
C2 - 15338749
AN - SCOPUS:4444350365
SN - 0921-4410
VL - 21
SP - 259
EP - 274
JO - Cancer chemotherapy and biological response modifiers
JF - Cancer chemotherapy and biological response modifiers
ER -